Colchicine

Generic Name: Colchicine

Brand Names: Colcrys, Gloperba, Lodoco, Mitigare

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅NO_₆

CAS Number: 64-86-8

Unique Ingredient Identifier: SML2Y3J35T

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.

Indication: Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.

Associated Conditions: Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke

Clinical Trials

The COLchicine and Atrial FIBrillation Trial

Phase 3

Recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Colchicine
Drug: Placebo

First Posted Date: 2023-07-03

Last Posted Date: 2024-02-28

Lead Sponsor: Herlev and Gentofte Hospital

Target Recruit Count: 500

Registration Number: NCT05928728

Locations: 🇩🇰
Center for Translational Cardiology and Pragmatic Randomized Trials (CTCPR), Hellerup, Denmark

Probiotic and Colchicine in COVID-19

Not Applicable

Completed

Conditions: COVID-19

Interventions: Drug: Colchicine 0.5 MG
Dietary Supplement: Probiotic Formula
Other: Standard protocol

First Posted Date: 2023-06-20

Last Posted Date: 2023-06-23

Lead Sponsor: Ain Shams University

Target Recruit Count: 150

Registration Number: NCT05911022

Locations: 🇪🇬
Ain Shams University, Cairo, Egypt

Colchicine After Electrocardioversion for Atrial Fibrillation

Phase 3

Recruiting

Conditions: Atrial Fibrillation
Cardiac Arrhythmia

Interventions: Drug: Placebo
Drug: Colchicine

First Posted Date: 2023-06-06

Last Posted Date: 2024-04-17

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 416

Registration Number: NCT05890664

Locations: 🇨🇭
Cantonal Hospital Baselland (KSBL), Bruderholz, Baselland, Switzerland
🇨🇭
University Hospital Basel, Basel, Switzerland
🇨🇭
University Hospital Bern, Bern, Switzerland

and more 1 locations

COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

Phase 3

Recruiting

Conditions: Heart Failure

Interventions: Drug: Colchicine 0.5 MG
Drug: Thiamine Mononitrate 300 mg
Drug: Colchicine placebo

First Posted Date: 2023-05-24

Last Posted Date: 2024-02-14

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 2500

Registration Number: NCT05873881

Locations: 🇨🇦
Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada

Colchicine Versus Placebo in Acute Myocarditis Patients

Phase 3

Recruiting

Conditions: Acute Myocarditis

Interventions: Drug: Colchicine Pill
Drug: Placebo

First Posted Date: 2023-05-11

Last Posted Date: 2025-01-17

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 300

Registration Number: NCT05855746

Locations: 🇫🇷
Unité de Soins Intensifs Cardiologiques - Hôpital Cardiovasculaire Louis Pradel, Bron, France
🇫🇷
Institut de Cardiologie - APHP Pitié Salpêtrière, Paris, France